What is melittin and why is a membrane-active peptide being considered against HIV-1?
Melittin is a 26-residue cationic amphipathic peptide with the sequence GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 and a molecular weight of about 2840 Da (Frontiers in Immunology, 2024). Its N-terminal region is predominantly hydrophobic while the C-terminal region is polar and cationic, so the peptide partitions into lipid bilayers and folds into an amphipathic α-helix (PMC7224078, 2019).
That structure produces a concentration-dependent outcome: insertion into the membrane, oligomerization, and pore formation that leaks ions and intracellular contents. The exact pore architecture remains debated, but the functional result is membrane disruption (PMC7224078, 2019). For an enveloped virus, a peptide that ruptures membranes is a plausible antiviral, and three anti-retroviral mechanisms have been proposed: direct virolysis of the viral membrane, permeabilization of the envelope, and suppression of viral gene expression (PMC7224078, 2019).
The problem is selectivity. Melittin is not intrinsically selective for viral membranes; it disrupts mammalian plasma membranes, especially erythrocytes (Frontiers in Immunology, 2024). Its reported HC50 against human red blood cells is 16.28 ± 0.17 µg/mL in a 2% suspension over 24 hours, and its LC50 against immature human dendritic cells is 43.42 ± 0.86 µg/mL (Frontiers in Immunology, 2024).
That is the whole evaluation problem in one number. I, b, not the antiviral value alone.
q. h 3,000 o, but only 7 m, 5 e: m, b, r, a, n (e, 2020). -.
What did the melittin-nanoparticle HIV-1 study actually show in vitro?
a 2.4 c 6.9 t (i), thiab 3.6 v 11.4 e (PubMed 22954649, 2013). The assay used TZM-bl reporter cells carrying luciferase under the HIV-1 promoter, with soluble CD4 as the positive control, which itself gave IC50 values of 3.7 µg/mL against CXCR4-tropic virus and 0.03 µg/mL against CCR5-tropic virus (PubMed 22954649, 2013).
Two absences matter as much as the numbers. First, the antiviral review that tabulates these EC50 values records CC50 and selectivity index as not determined (PMC7224078, 2019). No selectivity index was ever published for this particle, so anyone quoting a therapeutic window is computing something the authors did not. Thib ob, no second laboratory has reproduced the values in the sources reviewed here; the 2.4 v 3.6 µM pair appears in press coverage and downstream reviews, but all of it traces to this one paper.
The formulation itself is specific and worth stating precisely. The carrier is an inert perfluorooctyl bromide core with a unilamellar lipid surfactant shell, and melittin binds and inserts into that shell (PLoS ONE, 2014). The lipid surfactant co-mixture was 98.9 mol% egg lecithin, 0.1 mol% DiI, thiab 1 mol% carboxy-PEG-DSPE, with a lipid film at 2.0% w/v combined with perfluorooctyl bromide at 20% w/v (PLoS ONE, 2014).
Free melittin below 2 µM was not cytotoxic to the reporter cells and was highly effective against both strains, while the nanoparticle was reported as safe against VK2 vaginal epithelial cells at the doses tested (PubMed 22954649, 2013). The authors’ own framing was that future investigations appeared warranted to explore prophylactic potential, which is the correct register for a first in vitro result (PubMed 22954649, 2013).
How do you judge whether the antiviral effect is separable from host-membrane damage?
The companion study supplies the paired values that make the judgment possible. Free melittin had a VK2 vaginal epithelial cell viability IC50 of 1.3 µM, reduced vaginal cell viability at 1 µM and above, and reduced sperm motility and viability above 2 µM, with 8 µM or more eliminating both (PLoS ONE, 2014).
Compare antiviral activity with host-cell viability using matched formulation, concentration basis, exposure duration and relevant cells. Values from different studies cannot establish a definitive selectivity index or prove that free peptide fails in every context.
Isotope Labeled Peptides Manufacturer Neoantigen Synthesis Nanoparticle incorporation shifts the toxicity threshold, and that shift is the actual finding. Melittin nanoparticles were toxic to vaginal epithelium only at equivalent melittin concentrations of 20 µM or above, and to sperm only at 40 µM or above, a fivefold reduction in cytotoxicity relative to free melittin (PLoS ONE, 2014). The same paper reports no cytotoxicity to sperm or vaginal epithelium at an equivalent melittin concentration of 10 µM, which is above the 2.4 v 3.6 µM antiviral values.
The sources quantify that protection differently, and the difference is worth knowing. s 2013 abstract states VK2 viability was unaffected at any dose of melittin-loaded nanoparticles tested, while the 2014 companion paper gives the specific figures of 10 µM tolerated and 20 µM as the first toxic concentration (Neuropeptide Y Synthesis href=”https://pubmed.ncbi.nlm.nih.gov/22954649/”>PubMed 22954649, 2013; PLoS ONE, 2014). The later, more specific source is the one to quote, because “any dose” is broader than the data support.
A fivefold shift is not a therapeutic index. It is a shift in one assay on one cell type, and the same paper states that further testing is needed to determine cytotoxicity in a more physiologically relevant model system (PLoS ONE, 2014). Treat the fivefold figure as a formulation effect worth pursuing, not as a safety margin.
What formulation attributes define the product, not just the experiment?
The attributes that define the product are the ones a regulator would ask you to control, and the FDA guidance for liposome drug products lists them directly: mean particle size and size distribution, morphology and lamellarity, zeta potential or net charge, encapsulation efficiency, free drug controlled separately from encapsulated drug, and validated in-vitro release testing (FDA, 2018).
That guidance is written for liposomes, and the melittin carrier is a perfluorocarbon emulsion with a lipid monolayer, not a bilayer liposome (PMC2710241, 2008). Applying it here is an analogy a reviewer would expect you to justify, not a stated requirement. The attribute list still holds, because each item changes what the product is.
Size and surface charge were characterized during formulation development: the core-shell particle diameter was about 290 nm with no change after melittin addition (289.8 nm), and zeta potential shifted from −17.2 mV without melittin to +17.82 mV at a lipid-to-melittin ratio of 30 (PMC2710241, 2008). Those are development values, not a release specification, thiab qhia lawv raws li ib tug yuav hais tsis raug qhov ntsuas.
Qhov monolayer piav qhia vim li cas tus nqa khoom thiaj ciaj sia. Melittin txuas cov nanoparticles perfluorocarbon nrog ib qho kev cais tawm kwv yees li 3.27 nM, siv qauv α-helical nrog circular dichroism minima ntawm 208 thiab 220 nm, thiab muab Trp-19 zais ze ntawm perfluorocarbon interface (PMC2710241, 2008). Qhov chaw tib yam qhia tias muaj qauv monolayer ruaj khov ntawm electron microscopy tom qab ntxiv melittin, sib piv rau bilayer liposomes uas qhia kev cuam tshuam.
Qhov loj txiav ob sab, thiab cov chaw tsis pom zoo txog txoj kev. Daim ntawv phooj ywg hais tias 250 to 300 nm diameter tej zaum yuav thaiv kev nkag mus rau hauv lub cev epithelial barrier thiab txo kev nqus hauv lub cev (PLoS ONE, 2014), thaum kev tshuaj xyuas kev xa khoom hais tias qhov loj tib yam tej zaum tsis haum rau diffusion thiab cellular uptake ntawm qhov chaw (PMC8773652, 2022). I, b.
Why doesn’t a reporter-cell assay predict mucosal or repeated-dose performance?
q. h, o, especially CD4 T cells, k (e, 2015).
v. The melittin nanoparticle was tested against NLHX and NLYU2, n (PubMed 22954649, 2013). t, and not just laboratory-adapted strains, is important because transmitted/founder viruses have unique features (e, 2015). Read together, the particle has not been tested against the strain class the field considers most relevant to transmission.
Seminal plasma is the third gap, and it bears directly on a virus-targeting virucide. Seminal plasma increased the IC50 of inhibitors against reverse transcriptase, integrase, and protease by 8 to 21 fold, while the CCR5 inhibitor maraviroc, which targets a cellular component, remained potent (e, 2015). Melittin nanoparticles are described as capturing and disrupting the virion, which makes them virus-targeting, and no source reviewed here reports melittin activity in the presence of seminal plasma.
The review also notes that explant studies require exceedingly high viral doses to establish infection and are therefore unsuitable for low, physiologically relevant inocula, and that toxicity induced by a candidate can be mistaken for antiviral activity (e, 2015). That last point is the trap for any membrane-active agent: a peptide that kills the cells can look like a peptide that stops the virus.
Repeated-dose mucosal exposure adds a regulatory layer the single-dose assay does not touch. Topical prevention products are assessed with repeated-dose vaginal toxicity in two species, fertility and reproductive toxicity studies, and local-irritation testing (FDA, Peptide Manufacturers Wholesale 2005), and the vaginal microbicide guidance recommends assessing cervicovaginal inflammation and epithelial disruption (FDA, 2014). A 48-hour luciferase readout says nothing about any of it.
What analytical characterization and records does a reviewer need?
Start with the specification framework, because it is easy to get wrong. For a chemically synthesized peptide the principal framework is ICH Q6A, since ICH Q6B expressly excludes synthetic peptides (ICH, 1999). Confirm the Q6A scope sentence against the current text before filing, because the applicability statement is the part reviewers check first.
Design stability studies for the intended formulation, container, route and storage claim. General ICH chamber examples are not automatically the required conditions for a topical perfluorocarbon emulsion. Characterize peptide integrity, free and associated peptide, particle properties and activity over the justified period.
No source reviewed here reports melittin nanoparticle stability under any of those conditions. The companion paper reports only that size and zeta potential confirmed stability at vaginal pH for at least three days (PLoS ONE, 2014), which is not an ICH storage condition. That gap is the difference between a formulation that survives an experiment and one with a shelf life.
For an injectable, the sterility and endotoxin expectations are named chapters: USP <71> Sterility Tests, USP <85> Bacterial Endotoxins Test, i <788> Particulate Matter in Injections (USP, current). The numeric limits live in the chapter text and should be cited from there rather than from a summary.
The FDA liposome guidance adds a manufacturing expectation that is easy to miss: Kev huv si thiab tsis muaj pyrogens lossis kab mob endotoxins yuav tsum tau qhia, Cov txheej txheem ntxuav thiab tua kab mob tshwj xeeb rau cov khoom uas tau lees paub yuav tsum qhia tau tias cov lim sterilizing ua haujlwm yam tsis cuam tshuam rau kev ruaj ntseg ntawm cov hmoov av, Kev tswj endotoxin yuav tsum tau saib xyuas hauv txheej txheem tsim khoom es tsis yog tsuas yog los ntawm kev kuaj khoom tiav xwb (FDA, 2018).
Ib pob khoom tshawb fawb yuav tsum txuas kev txheeb xyuas, Cov ntsiab lus Peptide, Peptide dawb thiab cov peptide uas cuam tshuam, Qhov loj thiab faib ntawm cov khoom me me, Kev them nqi saum npoo, Kev tso tawm thiab kev tswj xyuas kab mob uas tsim nyog rau hauv pawg kuaj. Ntxiv microbiological, Endotoxin thiab cov qauv tsim raws li txoj kev, Theem thiab kev tsim qauv es tsis txhob xa tag nrho cov kev xav tau txhaj tshuaj rau hauv ib qho qauv sab nraud. Peptide Production Manufacturer
What evidence is still missing before clinical or commercial claims are justified?
The reference 2024 review did not establish clinical efficacy or safety of melittin for HIV prevention. This is a dated evidence statement, not a comprehensive current registry assessment of every melittin formulation or indication.
No source reviewed here reports an in vivo efficacy result for a melittin nanoparticle vaginal virucide. The companion paper states the long-term goal is a vaginal gel-based platform and that additional safety and efficacy experiments in animal models more closely simulating the vaginal environment are required (PLoS ONE, 2014). The primary paper calls its data a first proof of concept and says future investigations appear warranted (PubMed 22954649, 2013).
The mechanism is also unresolved in a way that changes what you would measure. s 2013 abstract frames the particle as capturing and disrupting virus, while the antiviral review states the cumulative evidence indicates the dose-dependent anti-HIV effect works by suppressing HIV transcription and lowering viral gene products rather than by lysis of cellular or viral membranes (PubMed 22954649, 2013; PMC7224078, 2019). These are competing readings, not a settled one, and they imply different assays and different failure modes.
Two more gaps are worth naming. Reported drug loading for melittin carriers sits in the single-digit percent range, with one PLGA formulation reaching about 90% loading efficiency and 6 to 7% drug content after ion-pairing (PMC8773652, 2022); those values belong to that specific carrier and should never be merged into one benchmark. And the plasma half-life extension figures appear only in the review, not in any primary formulation paper reviewed here (PMC8773652, 2022). Nmm Peptide Synthesis
The evidence ladder, in order: kev luam tawm ywj pheej ntawm IC50 tus nqi, ib qho selectivity index luam tawm, kev ua haujlwm tiv thaiv cov kab mob kis/tsim hauv thawj CD4 T hlwb, kev ua haujlwm hauv qhov muaj seminal plasma thiab cervicovaginal kua, kev puas tsuaj ntawm cov mucosal rov qab hauv ob hom tsiaj, cov ntaub ntawv ruaj khov hom ICH, thiab ib qho txiaj ntsig ua haujlwm hauv lub cev. Txog thaum cov theem ntawd puv, kev piav qhia ncaj ncees txog melittin nanoparticles thiab HIV-1 yog ib qho cim hauv vitro uas muaj tus nqa kab mob zoo thiab tsis tau pom txoj kev kho mob.
Cov Lus Nug Nquag Nug
Have melittin nanoparticles been tested in humans?
Cov kev tshawb fawb nanoparticle HIV-1 uas tau hais yog preclinical thiab tsis tau qhia txog kev ua haujlwm lossis kev nyab xeeb hauv kev kho mob. s 2024 kev tshuaj xyuas txog cov pov thawj ntawm tib neeg laus lawm; nws tsis tuaj yeem qhia tau tias tsis muaj kev tshawb fawb melittin hauv tib neeg txog lub Kaum Hli 2026. Tsab ntawv no tsis muaj kev thov kev sim tshuaj kho mob dav dav tam sim no.
Has the 2013 melittin nanoparticle HIV-1 result been replicated?
Tsis muaj nyob rau hauv cov ntaub ntawv uas tau tshuaj xyuas ntawm no. Cov haujlwm cytolytic-nanoparticle qub yog ib daim ntawv tshaj tawm xwb, thiab tsis muaj pab pawg ywj pheej twg pom tias tib yam particle tiv thaiv HIV-1 tshwm sim hauv cov pov thawj no. Qhov ntawd tseem ceeb rau qhov hnyav ntawm qhov tshwm sim: Ib qho kev tshawb fawb hauv lab hauv vitro yog qhov pib rau melittin nanoparticles thiab HIV-1 kev tshawb fawb, tsis yog ib qho kev tshawb fawb ruaj khov.
What is the selectivity index of melittin nanoparticles?
Cov ntaub ntawv sau tseg ntawm no tsis tsim tau ib qho selectivity index uas sib piv ncaj qha rau cov khoom uas tau npaj. Xam ib qho tsuas yog los ntawm qhov kawg antiviral thiab cytotoxicity uas sib txuas zoo, nrog kev tsis paub tseeb thiab cov xwm txheej assay tau hais.
Are melittin nanoparticles safe for vaginal use?
Qhov lus teb ncaj ncees yog tias tsis muaj leej twg tau qhia tias lawv. Nanoparticle-associated melittin tau txais kev txais tos txog 20 μM hauv ob hom hlwb, kev txhim kho tsib npaug piv rau melittin dawb (PLoS ONE, 2014). That is a cytotoxicity comparison in cultured cells, and the paper itself calls for testing in a more physiologically relevant model. No repeated-dose, local-irritation or in vivo data exist.
How do melittin nanoparticles compare with approved antiretrovirals?
They have not been compared. In the primary HIV-1 study the positive control was soluble CD4, not an approved drug (PubMed, 2013). No head-to-head against any licensed antiretroviral appears in this source set, so no potency ranking against current therapy can be drawn from the available data.
Can a peptide supplier support this kind of work?
Yog, within defined limits. A synthesis partner can contribute sequence design and modification, purity and identity documentation, sterile and low-endotoxin handling, and continuity from small-batch trial production to larger scale. What a supplier cannot do is establish antiviral efficacy or mucosal safety; those remain questions for the laboratory work described above.
Xaus lus
The melittin nanoparticle result is real, specific, and narrow. A perfluorocarbon particle with a lipid monolayer carried melittin to IC50 values of 2.4 v 3.6 µM against two laboratory-adapted HIV-1 strains in a reporter-cell assay, and the same formulation shifted melittin’s cytotoxicity threshold fivefold in the companion study (PubMed 22954649, 2013; PLoS ONE, 2014).
What the evidence does not support is any claim beyond that. There is no published selectivity index, no independent replication, no transmitted/founder strain data, no seminal plasma data, no ICH-format stability, no in vivo efficacy, and no human trial. The translational evidence for antiviral peptides of this class is thin for a reason, thiab qhov 7 FDA approvals out of more than 3,000 identified peptides is the shape of that record (e, 2020).
The practical takeaway for anyone evaluating a membrane-active peptide result is the paired-value rule. Never accept an antiviral potency figure without a host-membrane toxicity threshold measured in the same units on the relevant cell type, and never accept a formulation claim without the attribute data that define the product: size, charge, Peptide dawb thiab cov peptide uas cuam tshuam, release, x, and endotoxin. Apply that test to the next result you read, including this one, and the in vitro signal stays in its proper place.
